Study to Assess the Safety and Tolerability After Multiple Oral Doses of AZD1656 in Patients With Type 2 Diabetes Mellitus Treated With Metformin
Primary Purpose
Type 2 Diabetes
Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
AZD1656
Placebo
Sponsored by

About this trial
This is an interventional treatment trial for Type 2 Diabetes focused on measuring Type II Diabetes
Eligibility Criteria
Inclusion Criteria:
- Male or women of non-childbearing potential (postmenopausal, and/or have undergone hysterectomy and/or bilateral oophorectomy or salpingectomy/ tubal ligation)
- Ongoing treatment with metformin on a stable dose of ≥ 1500 mg/day for at least 8 weeks prior to randomisation
- HbA1c ≤ 10% at enrolment (HbA1c value according to international Diabetes Control and Complications Trial [DCCT] standard)
Exclusion Criteria:
- History of ischemic heart disease, symptomatic heart failure, stroke, transitory ischemic attack or symptomatic peripheral vascular disease
- Clinically significant abnormalities in ECG, clinical chemistry, haematology, or urine analysis results. Positive test for Hepatitis B surface antigen or antibodies to human immunodeficiency virus (HIV) or antibodies to Hepatitis C virus
Sites / Locations
- Research Site
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
AZD1656
Placebo
Arm Description
Dose titration of oral suspension during 4 days to a tolerable dose given twice daily. Subjects will thereafter be treated with this dose twice daily for another 24 days
Dose titration of oral suspension during 4 days to a tolerable dose given twice daily. Subjects will thereafter be treated with this dose twice daily for another 24 days
Outcomes
Primary Outcome Measures
Systolic Blood Pressure, Change From Baseline to End of Treatment
Diastolic Blood Pressure, Change From Baseline to End of Treatment
Pulse, Change From Baseline to End of Treatment
Weight, Change From Baseline to End of Treatment
Clinically Relevant Change of Laboratory Variables
Number of participants with clinically relevant change of laboratory variables (clinical chemistry, haematology and urinalysis parameters
Secondary Outcome Measures
Area Under the Plasma Concentration vs Time Curve (AUC0-24) of AZD1656
Dose-adjusted to a total daily dose of 100 mg due to titrated doses
Maximum Plasma Concentration of AZD1656
Dose-adjusted to a morning dose of 50 mg due to titrated doses
Time to Reach Maximum Plasma Concentration of AZD1656
Terminal Elimination Half-life of AZD1656
Apparent Oral Clearance of AZD1656
P-Glucose (AUC0-24)/24, Change From Baseline to End of Treatment
Log ratio (End of treatment/Baseline) has been analysed in a mixed-effect ANOVA model, using treatment as fixed effect and log(Baseline) as covariate. Resulting estimates have been back-transformed from the log-scale and then multiplied by 100 to obtain the relative ratio (end of treatment/placebo) in percent.
S-Insulin (AUC0-24)/24, Change From Baseline to End of Treatment
Log ratio (End of treatment/Baseline) has been analysed in a mixed-effect ANOVA model, using treatment as fixed effect and log(Baseline) as covariate. Resulting estimates have been back-transformed from the log-scale and then multiplied by 100 to obtain the relative ratio (end of treatment/placebo) in percent.
S-C-Peptide (AUC0-24)/24, Change From Baseline to End of Treatment
Log ratio (End of treatment/Baseline) has been analysed in a mixed-effect ANOVA model, using treatment as fixed effect and log(Baseline) as covariate. Resulting estimates have been back-transformed from the log-scale and then multiplied by 100 to obtain the relative ratio (end of treatment/placebo) in percent.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00817778
Brief Title
Study to Assess the Safety and Tolerability After Multiple Oral Doses of AZD1656 in Patients With Type 2 Diabetes Mellitus Treated With Metformin
Official Title
A Randomised, Single-Blind, Placebo-Controlled, Phase IIA Study to Assess the Safety and Tolerability After Multiple Oral Doses of AZD1656 in Patients With Type 2 Diabetes Mellitus Treated With Metformin
Study Type
Interventional
2. Study Status
Record Verification Date
October 2012
Overall Recruitment Status
Completed
Study Start Date
January 2009 (undefined)
Primary Completion Date
July 2009 (Actual)
Study Completion Date
July 2009 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
AstraZeneca
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to assess the 1 month safety and tolerability after multiple oral doses of AZD1656 in patients with Type 2 Diabetes Mellitus Treated with Metformin
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes
Keywords
Type II Diabetes
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
27 (Actual)
8. Arms, Groups, and Interventions
Arm Title
AZD1656
Arm Type
Experimental
Arm Description
Dose titration of oral suspension during 4 days to a tolerable dose given twice daily. Subjects will thereafter be treated with this dose twice daily for another 24 days
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Dose titration of oral suspension during 4 days to a tolerable dose given twice daily. Subjects will thereafter be treated with this dose twice daily for another 24 days
Intervention Type
Drug
Intervention Name(s)
AZD1656
Intervention Description
Subjects will be treated with tolerable dose twice daily for another 24 days.
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Subjects will be treated with tolerable dose twice daily for another 24 days.
Primary Outcome Measure Information:
Title
Systolic Blood Pressure, Change From Baseline to End of Treatment
Time Frame
Baseline is pre-dose first day of dosing, end of treatment is the morning following the treatment period
Title
Diastolic Blood Pressure, Change From Baseline to End of Treatment
Time Frame
Baseline is pre-dose first day of dosing, end of treatment is the morning following the treatment period
Title
Pulse, Change From Baseline to End of Treatment
Time Frame
Baseline is pre-dose first day of dosing, end of treatment is the morning following the treatment period
Title
Weight, Change From Baseline to End of Treatment
Time Frame
Baseline is the day before first dose, end of treatment is last day of treatment
Title
Clinically Relevant Change of Laboratory Variables
Description
Number of participants with clinically relevant change of laboratory variables (clinical chemistry, haematology and urinalysis parameters
Time Frame
Measured regularly from day before first dose to day after last dose
Secondary Outcome Measure Information:
Title
Area Under the Plasma Concentration vs Time Curve (AUC0-24) of AZD1656
Description
Dose-adjusted to a total daily dose of 100 mg due to titrated doses
Time Frame
Measured last day of treatment
Title
Maximum Plasma Concentration of AZD1656
Description
Dose-adjusted to a morning dose of 50 mg due to titrated doses
Time Frame
Measured last day of treatment
Title
Time to Reach Maximum Plasma Concentration of AZD1656
Time Frame
Measured last day of treatment
Title
Terminal Elimination Half-life of AZD1656
Time Frame
Measured following the afternoon dose last day of treatment
Title
Apparent Oral Clearance of AZD1656
Time Frame
Measured last day of treatment
Title
P-Glucose (AUC0-24)/24, Change From Baseline to End of Treatment
Description
Log ratio (End of treatment/Baseline) has been analysed in a mixed-effect ANOVA model, using treatment as fixed effect and log(Baseline) as covariate. Resulting estimates have been back-transformed from the log-scale and then multiplied by 100 to obtain the relative ratio (end of treatment/placebo) in percent.
Time Frame
Baseline is the day before first dose, end of treatment is last day of treatment
Title
S-Insulin (AUC0-24)/24, Change From Baseline to End of Treatment
Description
Log ratio (End of treatment/Baseline) has been analysed in a mixed-effect ANOVA model, using treatment as fixed effect and log(Baseline) as covariate. Resulting estimates have been back-transformed from the log-scale and then multiplied by 100 to obtain the relative ratio (end of treatment/placebo) in percent.
Time Frame
Baseline is the day before first dose, end of treatment is last day of treatment
Title
S-C-Peptide (AUC0-24)/24, Change From Baseline to End of Treatment
Description
Log ratio (End of treatment/Baseline) has been analysed in a mixed-effect ANOVA model, using treatment as fixed effect and log(Baseline) as covariate. Resulting estimates have been back-transformed from the log-scale and then multiplied by 100 to obtain the relative ratio (end of treatment/placebo) in percent.
Time Frame
Baseline is the day before first dose, end of treatment is last day of treatment
10. Eligibility
Sex
All
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Male or women of non-childbearing potential (postmenopausal, and/or have undergone hysterectomy and/or bilateral oophorectomy or salpingectomy/ tubal ligation)
Ongoing treatment with metformin on a stable dose of ≥ 1500 mg/day for at least 8 weeks prior to randomisation
HbA1c ≤ 10% at enrolment (HbA1c value according to international Diabetes Control and Complications Trial [DCCT] standard)
Exclusion Criteria:
History of ischemic heart disease, symptomatic heart failure, stroke, transitory ischemic attack or symptomatic peripheral vascular disease
Clinically significant abnormalities in ECG, clinical chemistry, haematology, or urine analysis results. Positive test for Hepatitis B surface antigen or antibodies to human immunodeficiency virus (HIV) or antibodies to Hepatitis C virus
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Klas Malmberg, MD, PhD, Prof
Organizational Affiliation
AstraZeneca R&D Mölndal
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Emanuel P DeNoia, M.D
Organizational Affiliation
Healthcare Discoveries LLC Icon Development Solutions
Official's Role
Principal Investigator
Facility Information:
Facility Name
Research Site
City
San Antonio
State/Province
Texas
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Study to Assess the Safety and Tolerability After Multiple Oral Doses of AZD1656 in Patients With Type 2 Diabetes Mellitus Treated With Metformin
We'll reach out to this number within 24 hrs